Soluble P‐tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
Soluble P‐tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau ; day:05 ; month:05 ; year:2021 ; extent:11
EMBO molecular medicine / European Molecular Biology Organization ; (05.05.2021) (gesamt 11)
- Urheber
-
Mattsson-Carlgren, Niklas
Janelidze, Shorena
Bateman, Randall J.
Smith, Ruben
Stomrud, Erik
Serrano, Geidy E.
Reiman, Eric M.
Palmqvist, Sebastian
Dage, Jeffrey L.
Beach, Thomas G.
Hansson, Oskar
- DOI
-
10.15252/emmm.202114022
- URN
-
urn:nbn:de:101:1-2021050515214224130972
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 14.08.2025, 08:50 UTC
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Mattsson-Carlgren, Niklas
- Janelidze, Shorena
- Bateman, Randall J.
- Smith, Ruben
- Stomrud, Erik
- Serrano, Geidy E.
- Reiman, Eric M.
- Palmqvist, Sebastian
- Dage, Jeffrey L.
- Beach, Thomas G.
- Hansson, Oskar
Ähnliche Objekte (12)
Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease
Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads
Towards a unified protocol for handling of CSF before β-amyloid measurements
Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer’s disease
Axonal degeneration and amyloid pathology predict cognitive decline beyond cortical atrophy
Relationship between amyloid and tau levels and its impact on tau spreading
Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease
Local structural preferences in shaping tau amyloid polymorphism
Tau neuropathology correlates with FDG-PET, but not AV-1451-PET, in progressive supranuclear palsy
Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease
Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease
Cortical microstructural associations with CSF amyloid and pTau
Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease
Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads
Towards a unified protocol for handling of CSF before β-amyloid measurements
Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer’s disease
Axonal degeneration and amyloid pathology predict cognitive decline beyond cortical atrophy
Relationship between amyloid and tau levels and its impact on tau spreading
Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease
Local structural preferences in shaping tau amyloid polymorphism
Tau neuropathology correlates with FDG-PET, but not AV-1451-PET, in progressive supranuclear palsy
Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease
Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease
Cortical microstructural associations with CSF amyloid and pTau
Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease
Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads
Towards a unified protocol for handling of CSF before β-amyloid measurements
Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer’s disease
Axonal degeneration and amyloid pathology predict cognitive decline beyond cortical atrophy
Relationship between amyloid and tau levels and its impact on tau spreading
Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease
Local structural preferences in shaping tau amyloid polymorphism
Tau neuropathology correlates with FDG-PET, but not AV-1451-PET, in progressive supranuclear palsy
Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease
Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease